• A compound, named SRI-KH001 or Kakeromycin as a drug candidate for anti-fungi at L1 stage.
  • A new chemical entity related to SRI-KH001, also effective to pathogenic fungi.
  • Under validation of novelty of  20 anti-fungi producing strains.
  • Total synthesis, chemical modification and lead optimization of SRI-KH001

Commission Service

  • Collaboration with NITE, National Institute of Technology and Evaluation


Future Prospects

  • Providing novel drug seeds by executing commissioned screening studies
  • Successive generation of anti-fungi drugs
  • Execution of screening of anti-virus drugs by use of our HTS technology that can be applied to disease types of virus, cancer, immune system, etc.